ProCE Banner Series

Precision Therapeutic Strategies in Gynecologic Oncology: Updates & Considerations for Managed Care Professionals

Live webinars with experts covering managed care precision therapeutic strategies in ovarian, endometrial, and cervical cancers, within a rapidly evolving landscape with new and emerging novel immunotherapy-based treatments and combinations, PARP inhibitors, and antibody–drug conjugates, from Clinical Care Options (CCO).

  ACPE-P
Credits Available

1.5

Who Should Attend

This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with ovarian, endometrial, and cervical cancers, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

All Events

Precision Therapeutic Strategies in Gynecologic Oncology: Updates & Considerations for Managed Care Professionals

Upcoming Events

April

25

2024

2:00 PM - 3:30 PM Central Time (CT)

Virtual

May

07

2024

2:00 PM - 3:30 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

ProCE Banner Faculty
Kelly Romo, PharmD, BCOP

Blue Cross Blue Shield of Michigan
Manager of Oncology Drug Management
Detroit, Michigan

Topics

Navigating Precision Ovarian Cancer Care: A Deep Dive Into Biomarkers, Therapies, and Evolving Paradigms

  • Managed care considerations for genetic testing and actionable biomarkers (eg, BRCA, (HRD), and FRα, and other biomarkers in development
  • Current best practices in managed care for ovarian cancer

Bridging Innovations and Clinical Outcomes in Endometrial Cancer: A Managed Care Perspective

  • Current indications for ICI plus chemotherapy
    • Managed care use of predictive and prognostic biomarkers defining the therapeutic landscape of endometrial cancers (dMMR/MSI, PD-L1, P53, and HER2)
    • Payers and pathway considerations for emerging biomarkers/therapies with Level 1 clinical evidence and guideline recommendations

Assessing for Potential of Combination Strategies and Novel Treatments in Cervical Cancer

  • Managed care approach to the use of immunotherapy ± chemotherapy in cervical cancer
  • Managed care insights on the role of ADCs in reshaping the treatment landscape in cervical cancer

Final Thoughts

Questions and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with gynecologic malignancies.

Target Audience
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with ovarian, endometrial, and cervical cancers, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Learning Objectives

  • Evaluate the cost-effectiveness and therapeutic implications of therapies for ovarian cancer patients, considering factors such as BRCA mutations or other homologous recombination repair deficiencies, to guide decisions in both frontline and relapsed settings

  • Assess the value proposition and patient-specific benefits of immune ICI-based therapies as first-line regimens for endometrial and cervical cancers, factoring in tumor attributes and patient demographics

  • Strategize a biomarker testing framework that optimally positions ADCs in treatment plans for patients with gynecologic malignancies

  • Determine patient cohorts with gynecologic cancers at a heightened risk of adverse outcomes, ensuring they have access to comprehensive educational resources and support from diagnosis through treatment phases, in line with managed care principles

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-24-006-L01-P has been assigned to this live application-based activity (initial release date 4/25/2024). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at http://www.ProCE.com , and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

Supported by educational grants from AstraZeneca and GlaxoSmithKline.